Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India's Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import and sell its cancer drug Durvalumab (branded as Imfinzi) in India for an additional use.
This new approval covers two dosage forms—120 mg/2.4 ml and 500 mg/10 ml—and expands Imfinzi's indication to treat adult patients with muscle invasive bladder cancer (MIBC). Specifically, the drug can now be used in combination with gemcitabine and cisplatin as a neoadjuvant (pre-surgery) treatment. After surgery (radical cystectomy), Imfinzi can continue as a standalone adjuvant (post-surgery) therapy.
The expanded label marks a significant milestone for AstraZeneca in India's oncology market, particularly in bladder cancer treatment. The company can now begin marketing Imfinzi for this new use, subject to any further clearances that may be needed.
Imfinzi is already approved globally for other cancer indications, including lung and biliary tract cancers. This latest CDSCO approval adds another layer to its growing clinical footprint in India.
AstraZeneca Pharma shares opened at ₹9,195.00 and touched a high of ₹9,650.50 during the day. The stock did not fall below its opening price, marking ₹9,195.00 as the low. Over the past year, the stock has seen a 52-week high of ₹10,691.00 and a low of ₹6,220.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Is This 1 Momentum Stock a Screaming Buy Right Now? Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. Astrazeneca (AZN) AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden's Astra AB and UK's Zeneca Group plc. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include CVRM (cardiovascular, renal and metabolism), Respiratory & Immunology (R&I), Oncology, Rare Diseases, Vaccines and Other. AZN boasts a Momentum Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Astrazeneca has seen some interesting price action recently; the stock is down 0.8% over the past one week and up 5.2% over the past four weeks. And in the last one-year period, AZN has lost 10%. As for the stock's trading volume, 5,003,182 shares on average were traded over the last 20 days. Momentum investors also pay close attention to a company's earnings. For AZN, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.04 to $4.54 per share for 2025. AZN boasts an average earnings surprise of 3.5%. AZN should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
5 hours ago
- Business Upturn
JK Lakshmi Cement to acquire 26% stake in renewable energy SPV Opera Vayu
By Aman Shukla Published on August 1, 2025, 19:17 IST JK Lakshmi Cement has announced that its Committee of Directors, in a meeting held on August 1, 2025, approved entering into a Power Purchase Agreement (PPA) and Share Subscription & Shareholders' Agreement with Opera Vayu (Narmada) Private Limited, a Special Purpose Vehicle (SPV) focused on renewable energy. As part of the agreement, JK Lakshmi Cement will acquire a 26% equity stake in the SPV for up to ₹4 crore. This strategic investment aligns with the company's goal to enhance renewable power sourcing and reduce energy costs at its manufacturing locations. The project involves setting up a 4 MWp wind and solar hybrid power plant under the captive power route. The SPV, incorporated on August 1, 2022, is backed by project implementor Shivman Wind Energy Private Limited. Though the SPV reported no turnover or profit as of FY25, it has a net worth of ₹77.56 crore. Following the acquisition, Opera Vayu (Narmada) will become an associate company of JK Lakshmi Cement, providing clean energy at competitive rates for 12 years. The transaction, not falling under related party arrangements, will be completed by December 31, 2025, and is structured as a cash deal. No regulatory approvals are required. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Wall Street Journal
8 hours ago
- Wall Street Journal
Global Pharma Stocks Fall After Trump Demands Cuts in Drug Prices
Global pharmaceutical stocks dropped after President Trump wrote to 17 companies asking them to cut the costs of drugs for U.S. consumers to the lowest price offered in other developed nations. Novo Nordisk, the maker of breakout drugs Ozempic and Wegovy, was among the hardest hit. Its shares slid more than 4% in Denmark on Friday. Shares in AstraZeneca, the maker of heartburn medication Nexium, fell more than 3% in London. Rival GSK fell more than 4%. Germany's Merck KGaA lost more than 2.5%. Trump wrote to the company's EMD Serono unit. In Switzerland, Roche and Novartis fell less than 1%. One of the president's letters was sent to Roche's Genentech arm. The move follows an executive order signed in May. Pharmaceuticals have also become a key focus in Trump's trade negotiations.
